Cited by 656Hormonal and reproductive studiesMenopause: Health Impacts and TreatmentsAdrenal Hormones and Disorders

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men

Wang, Christina, Cunningham, Glenn, Dobs, Adrian, Iranmanesh, Ali, Matsumoto, Alvin M., Snyder, Peter J., Weber, Thomas, Berman, Nancy +2 more·2004·The Journal of Clinical Endocrinology & Metabolism

Abstract

Transdermal testosterone (T) delivery represents an effective alternative to injectable androgens. We studied 163 hypogonadal men who applied 5, 7.5, or 10 g AndroGel (T gel) 1% CIII per day for up to 42 months. Efficacy data were presented in 123 subjects considered evaluable. Continuous AndroGel treatment normalized mean serum T and free T levels. Mean serum 5alpha-dihydrotestosterone concentrations and 5alpha-dihydrotestosterone/T ratio slightly increased, mean serum estradiol/T ratio doubled, and mean serum FSH and LH levels were suppressed by T replacement. Sexual function and mood parameters improved rapidly and were maintained throughout T treatment. Lean body mass increased (P = 0.0001) and fat mass decreased (P = 0.0001), and these changes were maintained with treatment but were not accompanied by significant increases in muscle strength. Increases in serum bone markers suggestive of increased bone formation were followed by gradual and progressive increases in bone mineral density more in the spine (P = 0.0001) than the hip (P = 0.0004). Mild local skin irritation occurred in 12 subjects, resulting in discontinuation in only one subject. Except for the anticipated increase in hematocrit and hemoglobin, there were no clinically significant changes in blood counts or biochemistry. In three subjects with elevated serum prostate-specific antigen, prostate biopsies showed cancer. We conclude that continued application of AndroGel resulted in beneficial effects similar to those with injectables and other transdermal preparations. This study was neither placebo controlled nor powered to determine the effects of T treatment on prostate cancer risk. Thus, monitoring for prostatic disease and assessment for erythrocytosis are strongly advised to reduce the risk of adverse events with T treatment of hypogonadal men.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2003-032006

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Testosterone replacement increases bone mineral density and improves trabecular structure and bone mechanical properties.

    “Treatment increases BMD (132-135) and improves trabecular structure (136) and bone mechanical properties (137).”
  • Prostate-specific antigen and prostate volume rise marginally and plateau at 12 months during testosterone treatment.

    “Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy.”
  • In a study of 123 subjects over 42 months of testosterone gel application, serum prostate-specific antigen significantly increases over the first 6 months and then shows no further significant increases with continued testosterone treatment.

    “In a study of 123 subjects over 42 months of testosterone gel application, there was significant increase in serum PSA over the first 6 months and then no further significant increases with continued testosterone treatment was found (87).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 48 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S.
Affiliations
  • University of California, Los Angeles (US)
  • Baylor College of Medicine (US)
  • Johns Hopkins University (US)
  • Veterans Health Administration (US)
  • University of Washington (US)
  • University of Pennsylvania Health System (US)
  • Duke Medical Center (US)
Corresponding author
Wang, Christina
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2004-05
Volume
89
Issue
5
Pages
2085-2098
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2001118572
Cited by
656
References
48
Citations by year
2026: 8 · 2025: 14 · 2024: 4 · 2023: 14 · 2022: 24 · 2021: 6 · 2020: 15 · 2019: 23 · 2018: 23 · 2017: 36 · 2016: 22 · 2015: 30 · 2014: 36 · 2013: 37 · 2012: 40
FWCI
32.97
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • University of Pennsylvania
  • Johns Hopkins University
  • Deutsches Krebsforschungszentrum
  • National Institutes of Health (RR00425)
  • National Center for Research Resources (M01RR000030, M01RR000425)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
testosterone replacement therapy, transdermal testosterone, hypogonadism, sexual function, mood, lean body mass, fat mass, bone mineral density, dihydrotestosterone, estradiol, gonadotropin suppression, erythrocytosis, prostate-specific antigen, prostate cancer risk, long-term treatment
MeSH terms
Adolescent, Adult, Affect, Aged, Androgens, Body Composition, Dose-Response Relationship, Drug, Drug Administration Schedule, Estradiol, Follicle Stimulating Hormone, Gels, Hematocrit, Hemoglobins, Humans, Hypogonadism, Luteinizing Hormone, Male, Prostatic Hyperplasia, Sexual Behavior, Sex Hormone-Binding Globulin, Testosterone, Ultrasonography, Biomarkers, Bone Density, Bone Remodeling, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review